Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.66 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301105 | 1.00 | HTT (0.68) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL607818 | 1.00 | HTT (0.68) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8340594 | 1.00 | HTT (0.68) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19658435 | 0.95 | EPHX1 (0.63) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL600676 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2466144 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1988494 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8029932 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL11266196 | 0.88 | KMT2A (0.67) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1568062 | 0.85 | KMT2A (0.71) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0192492-B1 | PEPTIDES CONTAINING AN ALIPHATIC-AROMATIC KETONE SIDE CHAIN | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1992-01-02 | — | — | EP | claimed |
| US-4332724-A | OXIDATION IN PRESENCE OF COBALT CATALYST | AMERICAN CYANAMID CO. (US) | 1982-06-01 | — | — | US | claimed |
| US-4254268-A | OXIDIZED BY POTASSIUM PERMANGANATE | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | claimed |
| EP-3356345-B1 | HETEROARYL DERIVATIVES AS SEPIAPTERIN REDUCTASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-08 | — | — | EP | disclosed |
| US-9951073-B2 | Compounds and compositions for treating chemical warfare agent-induced injuries | HYDRA BIOSCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-8952176-B2 | Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012175654-A1 | TETRALINE SULFONAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | FACULTES UNIVERSITAIRES NOTRE-DAME DE LA PAIX (BE) | 2012-12-27 | — | — | WO | disclosed |
| WO-2011143772-A1 | INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| EP-0253257-B1 | SUBSTITUTED AMINO-5,6,7,8-TETRAHYDRONAPHTHYL-OXYACETIC ACIDS, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | BAYER AG (DE) | 1990-11-14 | — | — | EP | disclosed |
| EP-0253257-A2 | Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, method for their preparation and their application as medicaments | BAYER AG (DE) | 1988-01-20 | — | — | EP | disclosed |
| US-4677193-A | GONADOTROPIN-RELEASING FACTOR ANALOGS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1987-06-30 | — | — | US | disclosed |
| EP-0192492-A2 | Peptides containing an aliphatic-aromatic ketone side chain | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1986-08-27 | — | — | EP | disclosed |
| US-4332724-A | OXIDATION IN PRESENCE OF COBALT CATALYST | AMERICAN CYANAMID CO. (US) | 1982-06-01 | — | — | US | disclosed |
| US-4254268-A | OXIDIZED BY POTASSIUM PERMANGANATE | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
| US-4199510-A | Process for oxidation of 4-amidotetrahydrobenzo [b]-thiophenes to 7-keto derivatives with cobaltic salts | AMERICAN CYANAMID COMPANY (US) | 1980-04-22 | — | — | US | disclosed |
| US-4091018-A | ANIMAL GROWTH PROMOTERS | AMERICAN CYANAMID COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-4049717-A | INTERMEDIATES FOR UREAS AND THIOUREAS | AMERICAN CYANAMID COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303521-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES | ELANE, CASP3, MMP8 | HTT 4377/4885ALDH1A1 1104/4885TAS1R3 3025/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | HTT 4284/4885ALDH1A1 374/4885TAS1R3 2580/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | HTT 832/4885ALDH1A1 1563/4885TAS1R3 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.